Clinical trial / 2022
Oral nicotinamide and pyruvate significantly improved visual field test locations in patients with open-angle glaucoma.
In a phase 2 trial, 42 patients with treated open-angle glaucoma were randomized 2:1 to ascending doses of oral nicotinamide (1000-3000 mg) and pyruvate (1500-3000 mg) or placebo, with 32 completing the study. Over a median follow-up of 2.2 months, the number of improving visual field test locations was significantly higher in the intervention group than placebo (median [IQR], 15 [6-25] vs 7 [6-11]; P = .005). Rates of change in pattern standard deviation suggested improvement (median, -0.06 vs 0.02 dB/week; P = .02), whereas mean deviation (P = .35) and visual field index (P = .71) did not differ significantly. No serious adverse events were reported.
- Study type
- Phase 2 randomized, double-blind, placebo-controlled trial
- Who was studied
- 32 completed participants with treated open-angle glaucoma and moderate visual field loss
- What was measured
- Visual field test locations improving beyond normal variability; rates of change of visual field global indices (MD, PSD, VFI)
THE PAPER
Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial.
De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. JAMA Ophthalmol, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.